Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205776 · ClinicalTrials.gov registry record · NA
EXCEL Clinical Trial
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 1,905
- Enrollment target
NCT01205776: Completed NA study, sponsored by Abbott Medical Devices.
NCT01205776 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,905 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01205776, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,905 participants
- Enrollment target
Study Summary
To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO \[for use outside the United States \[OUS\] only\]) in subjects with unprotected left main coronary artery disease by comparing to coronary artery bypass graft surgery.
Primary Outcome
All deaths includes Cardiac death, Vascular death and Non-cardiovascular death. Myocardial Infarction (MI): * Q wave MI: Development of new, pathological Q wave on the ECG. * Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves. Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent n
Interventions
- PROCEDURE CABG
- DEVICE Percutaneous Coronary Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,905 participants |
| Start Date | 2010-09-29 |
| Est. Completion | 2019-06-28 |
| Phase | NA |
What the finished NCT01205776 record still lists
NCT01205776 is an interventional study that assigns participants to a tested intervention. Its 1,905 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 2 interventions - of which CABG is the first listed.
NCT01205776 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01205776 about?
NCT01205776 is a clinical study titled "EXCEL Clinical Trial". To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO \[for use outside the United States \[OUS\] only\]) in subjects with unprotected left main coronary artery disease by comparing to corona...
What is the current status of trial NCT01205776?
This trial is currently completed. It is a NA study. The enrollment target is 1,905 participants. The study started on 2010-09-29. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT01205776?
The interventions under investigation include: CABG (PROCEDURE), Percutaneous Coronary Intervention (DEVICE).
Who is sponsoring clinical trial NCT01205776?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01205776's enrollment target sits among peer trials
1,905 55th of 2000 higher than 1,946 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI